SEC Form 4 · accession 0000899243-17-027196

scPharmaceuticals Inc. · SCPH

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Director

Period of report

Nov 21, 2017

Accepted (ET)

Nov 21, 2017 · 7:22 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001604950

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Nov 21, 2017	C	1,544,858	—	A	1,544,858	I	By: Lundbeckfond Invest A/S
Common Stock^F3,F2	Nov 21, 2017	C	984,366	—	A	2,529,224	I	By: Lundbeckfond Invest A/S

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F3,F4	—	Nov 21, 2017	C	11,092,383	D	—	—	Common Stock	1,544,858	0	I
Series B Preferred Stock^F3,F4	—	Nov 21, 2017	C	7,067,945	D	—	—	Common Stock	984,366	0	I

F1Represents the total number of shares of Common Stock received by Lundbeckfond Invest A/S ("LIAS"), upon conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
F2These shares are directly held by LIAS. The Reporting Person is the Managing Partner at Lundbeckfonden Ventures, which is the General Partner of LIAS. The reporting person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of all of the reported shares for purposes of Section 16 or any other purpose.
F3Represents the total number of shares of Common stock received by Lundbeckfond Invest A/S ("LIAS"), upon conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
F4All series of Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 7.180193-for-1 basis on November 21, 2017 and had no expiration date.